Manage Tickers

Has my stock been accused of fraud?Join over 160k users who know.

Ticker Price Change($) Change(%) Shares Volume Prev Close Open Gain($) Gain(%)
Ticker Status Jurisdiction Filing Date CP Start CP End CP Loss Deadline
Ticker Case Name Status CP Start CP End Deadline Settlement Amt
Ticker Name Date Analyst Firm Up/Down Target ($) Rating Change Rating Current
Analyst Rating Guide

News

Back

Autolus Therapeutics Q2 EPS $(0.18) Beats $(0.24) Estimate, Sales $20.923M Beat $12.905M Estimate

Author: Benzinga Newsdesk | August 12, 2025 06:05am
Autolus Therapeutics (NASDAQ:AUTL) reported quarterly losses of $(0.18) per share which beat the analyst consensus estimate of $(0.24) by 25 percent. This is a 18.18 percent increase over losses of $(0.22) per share from the same period last year. The company reported quarterly sales of $20.923 million which beat the analyst consensus estimate of $12.905 million by 62.13 percent.

Posted In: AUTL


CORE & Plaid

CORE Finalist

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION

CORE Finalist